Gram-positive infections: Pharmacy issues and strategy for quinupristin/dalfopristin

John C. Rotschafer, David H. Wright, Gigi H. Brown

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The development of the first streptogramin antibiotic, quinupristin/dalfopristin represents an attempt to bring new antimicrobial strategies on line to combat the menacing problem of Gram-positive-resistant bacteria. With introduction to the medical center formulary, the pharmacy will need to be aware of several practical issues surrounding the use of quinupristin/dalfopristin. Cost and unit size will be important issues. Initially, this drug will only be available in 500-mg vials which may not always accommodate the suggested dose of 7.5 mg/kg of actual body weight. In addition, the drug can only be reconstituted with D5W or sterile water, and it can not be mixed with normal saline, heparin, or other drugs. Institutions adding this drug to their formularies must address the expected logistical concerns with their medical, nursing, and pharmacy staffs prior to patient usage. Copyright (C) 1999 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)95-99
Number of pages5
JournalDiagnostic Microbiology and Infectious Disease
Issue number2
StatePublished - Feb 1999


Dive into the research topics of 'Gram-positive infections: Pharmacy issues and strategy for quinupristin/dalfopristin'. Together they form a unique fingerprint.

Cite this